Odapipam (INN ; developmental code names NNC 01-0756, NNC-756, NO-756) is a selective D1 receptor antagonist of the benzazepine group which was investigated as a potential antipsychotic but was never marketed.[1][2]
Clinical data | |
---|---|
Other names | NNC 01-0756; NNC-01-0756; NNC-010756; NNC010756; NNC01-0756; NNC-756; NNC756; NNC 0756; NNC0756; NO-756; NO756 |
Drug class | Dopamine D1 receptor antagonist |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C19H20ClNO2 |
Molar mass | 329.82 g·mol−1 |
3D model (JSmol) | |
| |
|
It has more than 5,000-fold selectivity for the dopamine D1 receptor (Ki = 0.17 nM) over the dopamine D2 receptor (Ki = 942 nM).[3] Its affinities for other dopamine receptors, such as the dopamine D5 receptor, were not reported.[3][4] In addition to the dopamine D1 receptor, odapipam showed relatively high affinity for the serotonin 5-HT2 receptor (Ki = 4.5 nM; 26-fold lower than for the D1 receptor).[4]
The drug was first described in the scientific literature by 1988.[4][5]
See also
edit- Berupipam (NNC 22-0010)
- Ecopipam (SCH-39166)
- NNC 01-0687 (ADX-10061)
- SCH-23390
References
edit- ^ Shen WW (1999). "A history of antipsychotic drug development". Compr Psychiatry. 40 (6): 407–414. doi:10.1016/s0010-440x(99)90082-2. PMID 10579370.
- ^ Seamans JK, Yang CR (September 2004). "The principal features and mechanisms of dopamine modulation in the prefrontal cortex". Prog Neurobiol. 74 (1): 1–58. doi:10.1016/j.pneurobio.2004.05.006. PMID 15381316.
- ^ a b Neumann J, Hofmann B, Dhein S, Gergs U (March 2023). "Role of Dopamine in the Heart in Health and Disease". Int J Mol Sci. 24 (5): 5042. doi:10.3390/ijms24055042. PMC 10003060. PMID 36902474.
- ^ a b c Andersen PH, Grønvald FC, Hohlweg R, Hansen LB, Guddal E, Braestrup C, Nielsen EB (August 1992). "NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists". Eur J Pharmacol. 219 (1): 45–52. doi:10.1016/0014-2999(92)90578-r. PMID 1397049.
- ^ Waddington JL (January 1989). "Functional interactions between D-1 and D-2 dopamine receptor systems: their role in the regulation of psychomotor behaviour, putative mechanisms, and clinical relevance". J Psychopharmacol. 3 (2): 54–63. doi:10.1177/026988118900300202. PMID 22156499.